...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of cardiovascular nursing >Rationale and design of the National Benchmarking and Evidence-based National Clinical Guidelines for Chronic Heart Failure Management Programs Study.
【24h】

Rationale and design of the National Benchmarking and Evidence-based National Clinical Guidelines for Chronic Heart Failure Management Programs Study.

机译：慢性心力衰竭管理计划研究的国家基准和循证国家临床指南的原理和设计。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: The National Benchmarks and Evidence-Based National Clinical Guidelines for Heart Failure Management Programs Study is a national, multicenter study designed to determine the nature, range, and effect of interventions applied by chronic heart failure management programs (CHF-MPs) throughout Australia on patient outcomes. Its primary objective is to use these data to develop national benchmarks and evidence-based clinical guidelines and optimize their cost-effective application by reducing quality and outcome variability. DATA SOURCES/STUDY SETTING: Primary data will be collected from CHF-MP coordinators and CHF patients enrolled in these programs on a national basis. Secondary outcome data will be collected from a national morbidity record and from patients' medical records. STUDY DESIGN: Stage I of the study involves a prospective clinical audit of all CHF-MPs throughout Australia (n = 45) to determine the extent of variability in programs currently. Stage II is a prospective cross-sectional survey design enrolling 1,500 patients (average of 40 patients per program) to firstly determine the typical profile of patients being managed via a CHF-MP in Australia and, secondly, the subsequent morbidity and mortality during the 6-month follow-up. Outcome data will be subject to multivariate analysis to determine the key components of care in this regard. All study data will be then examined in the final stage of the study (III) to develop national benchmarks for the application and auditing of CHF-MPs in Australia. CONCLUSION: Variability in patient outcomes is a product of heterogeneity among CHF-MPs. The development of national benchmarks will minimize such heterogeneity and will provide a greater level of evidence for their cost-effective application.
机译：目标：《国家标准和循证医学心力衰竭治疗计划国家临床指南》是一项全国性的多中心研究，旨在确定整个澳大利亚的慢性心力衰竭治疗计划（CHF-MP）采取的干预措施的性质，范围和效果关于患者的结果。其主要目标是利用这些数据来制定国家基准和基于证据的临床指南，并通过降低质量和结果变异性来优化其具有成本效益的应用。数据来源/研究设置：主要数据将从CHF-MP协调员和全国参与这些计划的CHF患者中收集。次要结果数据将从国家发病率记录和患者病历中收集。研究设计：研究的第一阶段涉及对整个澳大利亚（n = 45）的所有CHF-MP进行前瞻性临床审计，以确定当前计划的变异程度。第二阶段是一项前瞻性横断面调查设计，招募1,500名患者（每个程序平均40名患者），首先确定澳大利亚通过CHF-MP治疗的患者的典型特征，其次，确定这6个月中的随后发病率和死亡率个月的随访。结果数据将接受多变量分析，以确定这方面护理的关键组成部分。然后，将在研究的最后阶段（III）检查所有研究数据，以制定澳大利亚CHF-MP的应用和审核的国家基准。结论：患者预后的差异是CHF-MP之间异质性的产物。制定国家基准将最大程度地减少这种异质性，并为它们具有成本效益的应用提供更多的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号